PubRank

David G Binion

Author PubWeight™ 113.90‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013 7.81
2 Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003 3.49
3 Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 2002 2.67
4 Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr 2011 2.49
5 Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007 2.20
6 Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis 2009 2.03
7 Narcotic use in patients with Crohn's disease. Am J Gastroenterol 2005 1.83
8 Ambient air pollution correlates with hospitalizations for inflammatory bowel disease: an ecologic analysis. Inflamm Bowel Dis 2010 1.73
9 Navigation skill impairment: Another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology 2008 1.67
10 Simple score to identify colectomy risk in ulcerative colitis hospitalizations. Inflamm Bowel Dis 2010 1.67
11 Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells. Am J Physiol Cell Physiol 2004 1.61
12 Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008 1.57
13 A novel risk score to stratify severity of Crohn's disease hospitalizations. Am J Gastroenterol 2010 1.56
14 QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 2011 1.55
15 Food dye use in enteral feedings: a review and a call for a moratorium. Nutr Clin Pract 2002 1.45
16 Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am J Gastroenterol 2008 1.44
17 Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol 2003 1.44
18 Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology 2003 1.44
19 Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2010 1.41
20 Pain and inflammatory bowel disease. Inflamm Bowel Dis 2009 1.39
21 Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008 1.36
22 Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2007 1.29
23 The vascular contribution in the pathogenesis of inflammatory bowel disease. Am J Physiol Heart Circ Physiol 2003 1.23
24 CXCL12 activation of CXCR4 regulates mucosal host defense through stimulation of epithelial cell migration and promotion of intestinal barrier integrity. Am J Physiol Gastrointest Liver Physiol 2004 1.21
25 Human intestinal microvascular endothelial cells express Toll-like receptor 5: a binding partner for bacterial flagellin. J Immunol 2004 1.19
26 Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis 2009 1.19
27 Trends in ambulatory and emergency room visits for inflammatory bowel diseases in the United States: 1994-2005. Am J Gastroenterol 2009 1.16
28 Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J Gastrointest Surg 2007 1.15
29 Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2010 1.13
30 The intestinal microvasculature as a therapeutic target in inflammatory bowel disease. Ann N Y Acad Sci 2006 1.12
31 Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci 2012 1.10
32 Permanent work disability in Crohn's disease. Am J Gastroenterol 2007 1.07
33 Volume and yield of screening colonoscopy at a tertiary medical center after change in medicare reimbursement. Am J Gastroenterol 2003 1.05
34 Mechanisms of endotoxin tolerance in human intestinal microvascular endothelial cells. J Immunol 2003 1.03
35 Endothelial TLR4 activation impairs intestinal microcirculatory perfusion in necrotizing enterocolitis via eNOS-NO-nitrite signaling. Proc Natl Acad Sci U S A 2013 1.03
36 Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells. Am J Physiol Gastrointest Liver Physiol 2004 1.03
37 Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin North Am 2009 1.02
38 Effect of curcumin on acidic pH-induced expression of IL-6 and IL-8 in human esophageal epithelial cells (HET-1A): role of PKC, MAPKs, and NF-kappaB. Am J Physiol Gastrointest Liver Physiol 2008 1.02
39 Cyclosporin A differentially inhibits multiple steps in VEGF induced angiogenesis in human microvascular endothelial cells through altered intracellular signaling. Cell Commun Signal 2004 1.02
40 A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg 2010 1.00
41 Clostridium difficile and inflammatory bowel disease. Med Clin North Am 2010 0.99
42 Human esophageal microvascular endothelial cells respond to acidic pH stress by PI3K/AKT and p38 MAPK-regulated induction of Hsp70 and Hsp27. Am J Physiol Cell Physiol 2006 0.99
43 Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery 2003 0.99
44 Mucosal IgG4 cell infiltration in ulcerative colitis is linked to disease activity and primary sclerosing cholangitis. Inflamm Bowel Dis 2013 0.97
45 Five-Year Period Prevalence and Characteristics of Anemia in a Large US Inflammatory Bowel Disease Cohort. J Clin Gastroenterol 2016 0.96
46 The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis 2005 0.96
47 Case report: magnetic resonance imaging in the diagnosis of epidural abscess complicating perirectal fistulizing Crohn's disease. Inflamm Bowel Dis 2003 0.96
48 Chronic sinonasal disease in patients with inflammatory bowel disease. Am J Rhinol 2003 0.95
49 Role of hydrogen peroxide in ACh-induced dilation of human submucosal intestinal microvessels. Am J Physiol Heart Circ Physiol 2004 0.92
50 Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium. J Biol Chem 2002 0.91
51 Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007 0.91
52 Butyrate modulates gene and protein expression in human intestinal endothelial cells. Biochem Biophys Res Commun 2003 0.90
53 New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease. Inflamm Bowel Dis 2010 0.89
54 The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci 2009 0.89
55 Physician density and hospitalization for inflammatory bowel disease. Inflamm Bowel Dis 2011 0.89
56 Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002 0.89
57 Mesenteric venous thrombosis in inflammatory bowel disease. J Clin Gastroenterol 2005 0.88
58 History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. Inflamm Bowel Dis 2009 0.88
59 Successful treatment of an acute flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin. Inflamm Bowel Dis 2002 0.87
60 Expression of vascular cell adhesion molecule-1 (CD 106) in normal and neoplastic human esophageal squamous epithelium. Int J Oncol 2006 0.86
61 Treatment of ulcerative colitis in the elderly. Dig Dis 2009 0.86
62 Isolation and characterization of human esophageal microvascular endothelial cells: mechanisms of inflammatory activation. Am J Physiol Gastrointest Liver Physiol 2003 0.86
63 Radiographic underestimation of small bowel stricturing Crohn's disease: a comparison with surgical findings. Surgery 2004 0.86
64 The inflammatory bowel disease live interinstitutional and interdisciplinary videoconference education (IBD LIVE) series. Inflamm Bowel Dis 2014 0.86
65 Novel mechanism of vasodilation in inflammatory bowel disease. Arterioscler Thromb Vasc Biol 2005 0.86
66 Sodium butyrate inhibits angiogenesis of human intestinal microvascular endothelial cells through COX-2 inhibition. FEBS Lett 2003 0.85
67 Is inflammatory bowel disease a vascular disease? Targeting angiogenesis improves chronic inflammation in inflammatory bowel disease. Gastroenterology 2008 0.84
68 Smooth muscle cell proliferation induced by oxidized LDL-borne lysophosphatidylcholine. Evidence for FGF-2 release from cells not extracellular matrix. Vascul Pharmacol 2002 0.84
69 Antiangiogenic treatment of mesenteric desmoid tumors with toremifene and interferon alfa-2b: report of two cases. Dis Colon Rectum 2004 0.84
70 Impact of Obesity on the Management and Clinical Course of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2015 0.84
71 Abdominal pain in ulcerative colitis. Inflamm Bowel Dis 2013 0.83
72 Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm Bowel Dis 2009 0.83
73 Modulatory effect of curcumin on survival of irradiated human intestinal microvascular endothelial cells: role of Akt/mTOR and NF-{kappa}B. Am J Physiol Gastrointest Liver Physiol 2010 0.83
74 Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). Am J Physiol Gastrointest Liver Physiol 2009 0.82
75 Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003 0.82
76 Silent Crohn's Disease: Asymptomatic Patients with Elevated C-reactive Protein Are at Risk for Subsequent Hospitalization. Inflamm Bowel Dis 2015 0.82
77 Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016 0.82
78 The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2015 0.82
79 Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol 2005 0.81
80 Suppressive effects of cyclosporine A on neutrophils and T cells may be related to therapeutic benefits in patients with steroid-resistant ulcerative colitis. Inflamm Bowel Dis 2002 0.81
81 Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease? Inflamm Bowel Dis 2010 0.80
82 Role of MutS homolog 2 (MSH2) in intestinal myofibroblast proliferation during Crohn's disease stricture formation. Am J Physiol Gastrointest Liver Physiol 2008 0.80
83 Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease. Inflamm Bowel Dis 2010 0.80
84 Recurrent blood eosinophilia in ulcerative colitis is associated with severe disease and primary sclerosing cholangitis. Dig Dis Sci 2012 0.80
85 Laparoscopic resection for inflammatory bowel disease: outcomes from a nationwide sample. J Gastrointest Surg 2009 0.79
86 Expression of proteinase-activated receptor 2 on human primary gastrointestinal myofibroblasts and stimulation of prostaglandin synthesis. Can J Physiol Pharmacol 2005 0.79
87 Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review. Curr Drug Targets 2010 0.79
88 Managing Clostridium difficile in inflammatory bowel disease (IBD). Curr Gastroenterol Rep 2014 0.79
89 Supportive therapy in IBD: what additional diagnoses and conditions must be treated? Dig Dis 2010 0.78
90 Impact of autonomic dysfunction on inflammatory bowel disease. J Clin Gastroenterol 2010 0.78
91 Delineation of Crohn's Disease Trajectories Using Change in Lémann Index: A Natural History Study. J Clin Gastroenterol 2016 0.78
92 Durability of infliximab in Crohn's disease: a single-center experience. Inflamm Bowel Dis 2009 0.78
93 Patterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease: A 4-year Prospective Study. Inflamm Bowel Dis 2015 0.77
94 Quality of Sleep and Coexistent Psychopathology Have Significant Impact on Fatigue Burden in Patients With Inflammatory Bowel Disease. J Clin Gastroenterol 2016 0.77
95 Clinical course of Crohn's disease following treatment of lymphoma. Inflamm Bowel Dis 2011 0.76
96 Fracture-associated hospitalizations in patients with inflammatory bowel disease. Dig Dis Sci 2010 0.76
97 Clostridium difficile and inflammatory bowel disease: more questions than answers? Inflamm Bowel Dis 2010 0.75
98 Rituximab-induced remission of a gastric MALT lymphoma. Leuk Lymphoma 2004 0.75
99 The Cost of Crohn's Disease: Varied Health Care Expenditure Patterns Across Distinct Disease Trajectories. Inflamm Bowel Dis 2016 0.75
100 Editorial: improved efficacy of biological maintenance therapy in "early" compared with "late" Crohn's disease: strike while the iron is hot with anti-TNF agents? Am J Gastroenterol 2010 0.75
101 IBD LIVE Case Series-Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment? Inflamm Bowel Dis 2015 0.75
102 Case report: "Popcorn" dystrophic ileal calcification in a patient with Crohn's disease. Inflamm Bowel Dis 2003 0.75
103 IBD LIVE Case Series-Case 6: Persistent Skin Lesions in a Patient with Crohn's Disease: You Hear Hoof Beats and Discover a Zebra. Inflamm Bowel Dis 2016 0.75
104 IBD LIVE Case Series-Case 6. Inflamm Bowel Dis 2016 0.75
105 Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up: The Consequences of Under-reporting Active Inflammation. Inflamm Bowel Dis 2016 0.75
106 IBD LIVE Series-Case 7: The Brain-Gut Connection and the Importance of Integrated Care in IBD. Inflamm Bowel Dis 2017 0.75
107 IBD LIVE Case Series-Case 5: The Many Faces of Cytomegalovirus in Inflammatory Bowel Disease. Inflamm Bowel Dis 2016 0.75
108 Telephone Encounters Predict Future High Financial Expenditures in Inflammatory Bowel Disease Patients: A 3-Year Prospective Observational Study. J Clin Gastroenterol 2017 0.75
109 Multiyear Patterns of Serum Inflammatory Biomarkers and Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis. Inflamm Bowel Dis 2016 0.75
110 IBD LIVE Case Series-Case 4: Worms in IBD: Friend or Foe. Inflamm Bowel Dis 2016 0.75
111 Bowel rest and nutrition therapy in the management of active Crohn's disease. Nutr Clin Pract 2008 0.75
112 IBD LIVE Series-Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa. Inflamm Bowel Dis 2017 0.75
113 Effect of enteric flora on inflammatory and angiogenic mechanisms in human intestinal microvascular endothelial cells. Front Biosci 2005 0.75
114 Lasting Impact of Clostridium difficile Infection in Inflammatory Bowel Disease: A Propensity Score Matched Analysis. Inflamm Bowel Dis 2017 0.75